Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Eton Pharmaceuticals (ETON) over the last 6 years, with Q3 2025 value amounting to -$284000.0.

  • Eton Pharmaceuticals' Cash from Investing Activities changed N/A to -$284000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.4 million, marking a year-over-year decrease of 134584.12%. This contributed to the annual value of -$40.0 million for FY2024, which is 506309.68% down from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Cash from Investing Activities of -$284000.0 as of Q3 2025.
  • Eton Pharmaceuticals' 5-year Cash from Investing Activities high stood at -$2000.0 for Q3 2021, and its period low was -$38.1 million during Q4 2024.
  • For the 5-year period, Eton Pharmaceuticals' Cash from Investing Activities averaged around -$4.7 million, with its median value being -$768000.0 (2022).
  • Within the past 5 years, the most significant YoY rise in Eton Pharmaceuticals' Cash from Investing Activities was 9963.12% (2022), while the steepest drop was 9990000.0% (2022).
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' Cash from Investing Activities stood at -$3.3 million in 2021, then soared by 99.63% to -$12000.0 in 2022, then crashed by 6358.33% to -$775000.0 in 2023, then plummeted by 4820.26% to -$38.1 million in 2024, then soared by 99.26% to -$284000.0 in 2025.
  • Its last three reported values are -$284000.0 in Q3 2025, -$38.1 million for Q4 2024, and -$1.9 million during Q1 2024.